We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+60.06%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$883M
AUM Growth
-$53.7M
Cap. Flow
-$141M
Cap. Flow %
-15.97%
Top 10 Hldgs %
73.41%
Holding
37
New
4
Increased
6
Reduced
5
Closed
11

Top Buys

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$41.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$35.4M
3
ESPR
Esperion Therapeutics
ESPR
+$24M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$21.2M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$16.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$111M
2
LOXO
Loxo Oncology, Inc
LOXO
+$46.1M
3
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$24.5M
4
BPMC
Blueprint Medicines
BPMC
+$22.9M
5
PTCT icon
PTC Therapeutics
PTCT
+$21.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
26
Syndax Pharmaceuticals
SNDX
$1.69B
$702K 0.08%
100,000
– –
BPMC
27
DELISTED
Blueprint Medicines
BPMC
– –
-250,000
Closed -$22.9M
IONS icon
28
Ionis Pharmaceuticals
IONS
$8.6B
– –
-312,000
Closed -$13.8M
NGNE icon
29
Neurogene
NGNE
$656M
– –
-37,375
Closed -$10.5M
RIGL icon
30
CALL
Rigel Pharmaceuticals
RIGL
$681M
– –
-50,000
Closed -$1.77M
GTHX
31
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-660,000
Closed -$24.5M
BLCM
32
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-35,000
Closed -$2.3M
ONTXW
33
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
– –
-241,644
Closed -$72K
DERM
34
DELISTED
Dermira, Inc.
DERM
– –
-500,000
Closed -$4M
LOXO
35
DELISTED
Loxo Oncology, Inc
LOXO
– –
-400,000
Closed -$46.1M
AVXS
36
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-900,000
Closed -$111M
LJPC
37
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-267,500
Closed -$7.97M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Boxer Capital held 37 positions worth $883M, down 5.7% from $937M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Boxer Capital withdrew a net $141M in Q2 2018, closing 11 positions and reducing 5 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $111M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Sarepta Therapeutics worth $49.6M.

  • Boxer Capital's largest Q2 2018 buy was Sarepta Therapeutics: 375,000 shares worth $49.6M.
  • Boxer Capital added most to Solid Biosciences in Q2 2018, an estimated $41.6M increase.
  • Boxer Capital's biggest Q2 2018 reduction was PTC Therapeutics, cutting an estimated $21.8M.
  • Boxer Capital fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $111M.
  • Boxer Capital's ten largest holdings make up 73% of its $883M portfolio in Q2 2018.
  • Boxer Capital opened 4 new positions and closed 11 in Q2 2018.
  • Boxer Capital's portfolio value fell 5.7% quarter-over-quarter to $883M.

Based on Boxer Capital's 13F filing for Q2 2018, filed 14 Aug 2018.